AR077004A1 - Compuestos heterociclicos antivirales - Google Patents
Compuestos heterociclicos antiviralesInfo
- Publication number
- AR077004A1 AR077004A1 ARP100101992A ARP100101992A AR077004A1 AR 077004 A1 AR077004 A1 AR 077004A1 AR P100101992 A ARP100101992 A AR P100101992A AR P100101992 A ARP100101992 A AR P100101992A AR 077004 A1 AR077004 A1 AR 077004A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- oxo
- hydrogen
- independently
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- -1 2-oxo-1,2-dihydro-pyridin-3-yl Chemical group 0.000 abstract 19
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical group 0.000 abstract 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 abstract 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101100533877 Hypocrea jecorina (strain QM6a) sor8 gene Proteins 0.000 abstract 1
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Son inhibidores de la polimerasa NS5b del virus de la hepatitis C. Se describen también composiciones y métodos para tratar una infeccion del HCV e inhibir la replicacion del HCV. Reivindicacion 1: Un compuesto de la formula 1 en la que X1 es N y X2, X3 y X4 son CR5; o X1 y X2 son N, y X3 y X4 son CR5 ; o X1, X2 y X4 son CR5 y X3 es N; o X1 y X4 son N y X2 y X3 son CR5; o X1, X2, X3 y X4 son CR5; R1 es (a) un resto heteroarilo elegido entre el grupo formado por piridinilo, 2-oxo-1,2-dihidro-piridin-3-ilo, 3-oxo-3,4-dihidro-pirazin-2-ilo, 3-oxo-2,3-dihidro-piridazin- 4-ilo, 2-oxo-1,2-dihidro-pirimidin-4-ona-5-ilo, 6-oxo-1,6-dihidro-[1,2,4]triazin-5-ilo, 2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilo, 2-oxo-2(H)-piridin-1-ilo, 6-oxo-6H-piridazin-1-ilo, 6-oxo-6H-pirimidin-1-ilo y 2-oxo-2H-pirazin-1-ilo, dicho heteroarilo está opcionalmente sustituido por halogeno, alquilo C1-6, haloalquilo C1-3, hidroxialquilo C1-6, alcoxi C1-3-alquilo C1-3, alcoxi C1-6, X1(CH2)1-6CO2H o X1-(CH2)2-6NRgRh; o (b) un resto heterocíclico elegido entre el grupo formado por 2-oxo-tetrahidro-pirimidin-1-ilo, 2-oxo- imidazolidin-l-ilo, 2-oxo-piperidin-1-ilo, 2-oxo- pirrolidin-1-ilo, 2,6-dioxo-tetrahidro-pirimidin-1-ilo, 2,4-dioxo-1,2,3,4-tetrahidro-pirimidin-5-ilo, 2,5-dioxo-imidazolidin-1-ilo y 2, 4-dioxo-tetrahidro-pirimidin-1-ilo; R2 es hidrogeno, alcoxi C1-6, alquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6 o halogeno; R3 es (a) arilo, (b) heteroarilo, dicho arilo o dicho heteroarilo están opcionalmente sustituidos con independencia de una a tres veces por sustituyentes elegidos entre el grupo formado por hidroxi, alcoxi C1-6, alquilo C1-6, hidroxialquilo C1-6, halogeno, (CH2)nNRcRd, ciano, alcoxi C1-6-carbonilo, carbamoílo, N-alquilcarbamoílo, N,N-dialquil-carbamoilo, (CH2)0-3CO2H, SO2NH2, alquilsulfinilo C1-6 y alquilsulfonilo C1-6, o (c) NRaRb, (d) hidrogeno, (e) halogeno o (f) -X (R7)[C(R6)2-6 NReRf en el que X es O o NR7, y R7 es hidrogeno o alquilo C2-4, R6 es con independencia de cada aparicion hidrogeno, alquilo C1-3 o dos restos R6 sobre el mismo átomo de C son alquileno C2-5 o dos restos R6 sobre diferentes átomos de carbono son alquileno C1-4; Ra y Rb junto con el átomo de nitrogeno al que están unidos forman una amina cíclica sustituida con independencia de una a tres veces por grupos elegidos con independencia entre alquilo C1-6, halogeno y (CH2)nNReRf; Rc y Rd son con independencia hidrogeno, alquilo C1-6, haloalquilo C1-6, acilo C1-6, SOR8, en el que R8 es (a) alquilo C1-6, (b) haloalquilo C1-6, (c) cicloalquilo C3-7, (d) cicloalquil C3-7-alquilo C1-3, (e) alcoxi C1-6-alquilo C1-6 o (f) SO2[C(R9)2]0-6NRkRl, alquil C1-3-carbamoilo o di(alquil C1-3)-carbamoílo; Re y Rf son con independencia hidrogeno, alquilo C1-6, haloalquilo C1-6, acilo C1-6, SO2R8, en el que R8 es (a) alquilo C1-6, (b) haloalquilo C1-6, (c) cicloalquilo C3-7, (d) cicloalquil C3-7-alquilo C1-3, (e) alcoxi C1-6-alquilo C1-6, o (f) SO2[C(R9)2]0-6NRkRl; Ri y Rj son (i) con independencia hidrogeno, alquilo C1-3 o (CH2)2-6NRgRh o (ii) junto con el átomo de nitrogeno al que están unidos forman (CH2)2X5(CH2)2, en el que X5 es O o NRk y Rk es hidrogeno, alquilo C1-3, acilo C1-3 o alquil-sulfonilo C1-3; R4 es hidrogeno, CF3, CH2CF3, cicloalquilo C3-5, halogeno, alcoxi C1-6, haloalcoxi C1-3, CHR4aR4b o CR4aR4bR4c en los que (i) R4a, R4b y R4c se eligen con independencia entre alquilo C1-3, CD3, alcoxi C1-2, fluoralquilo C1-2, hidroxialquilo C1-3, ciano e hidroxi; o (ii) tomados juntos, R4a y R4b juntos son alquileno C2-4 y R4c es hidrogeno, alquilo C1-3, alcoxi C1-2, halogeno, hidroxialquilo C1-3, ciano o fluoralquilo C1-2 o R4a y R4b junto con el átomo de carbono al que están unidos forman un 3-oxetanilo o un tetrahidrofuran-2-ilo; R5 es con independencia de cada aparicion hidrogeno, halogeno, alcoxi C1-6 o alquilo C1-6; R8, Rg y Rh son con independencia en cada aparicion hidrogeno o alquilo C1-3; Rk y Rl son (i) con independencia en cada aparicion hidrogeno o alquilo C1-6 o (ii) junto con el nitrogeno al que están unidos Rk y Rl forman una amina cíclica; n es con independencia de cada aparicion un numero de cero a tres; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18546009P | 2009-06-09 | 2009-06-09 | |
| US26335109P | 2009-11-21 | 2009-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077004A1 true AR077004A1 (es) | 2011-07-27 |
Family
ID=42288900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101992A AR077004A1 (es) | 2009-06-09 | 2010-06-07 | Compuestos heterociclicos antivirales |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8026253B2 (es) |
| EP (1) | EP2440528B1 (es) |
| JP (1) | JP5612678B2 (es) |
| KR (1) | KR101431343B1 (es) |
| CN (1) | CN102803216B (es) |
| AR (1) | AR077004A1 (es) |
| AU (1) | AU2010257592B2 (es) |
| BR (1) | BRPI1010852A2 (es) |
| CA (1) | CA2764141C (es) |
| CO (1) | CO6400218A2 (es) |
| CR (1) | CR20110605A (es) |
| EC (1) | ECSP11011513A (es) |
| ES (1) | ES2525254T3 (es) |
| HK (1) | HK1176070A1 (es) |
| IL (1) | IL216412A (es) |
| MA (1) | MA33360B1 (es) |
| MX (1) | MX2011013209A (es) |
| MY (1) | MY157435A (es) |
| NZ (1) | NZ596646A (es) |
| PE (2) | PE20120937A1 (es) |
| RU (1) | RU2540332C2 (es) |
| SG (1) | SG176762A1 (es) |
| TW (1) | TWI428332B (es) |
| WO (1) | WO2010142656A1 (es) |
| ZA (1) | ZA201108921B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011008641A (es) * | 2009-03-06 | 2011-09-06 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| KR101445506B1 (ko) * | 2010-07-07 | 2014-09-26 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| CN103068819B (zh) * | 2010-08-13 | 2014-08-13 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| WO2013090929A1 (en) * | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | Amino quinoline derivatives inhibitors of hcv |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| KR20150070350A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Ror-감마-t의 페닐 결합 퀴놀리닐 조절제 |
| AU2013331496B2 (en) | 2012-10-16 | 2017-07-27 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ROR-gamma-t |
| WO2014062655A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt |
| WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
| CA2943100C (en) * | 2014-03-24 | 2017-04-04 | Hao Wu | Quinoline derivatives as smo inhibitors |
| EP3328839A1 (en) * | 2015-07-30 | 2018-06-06 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| CN111777549A (zh) * | 2020-07-07 | 2020-10-16 | 中瀚(齐河县)生物医药科技有限公司 | 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB558009A (en) * | 1942-05-08 | 1943-12-15 | Harold Coates | Quinoline derivatives |
| RU2029472C1 (ru) * | 1989-09-26 | 1995-02-27 | Сумитомо Кемикал Компани Лимитед | Производные урацила, промежуточные соединения, гербицидная композиция и способ борьбы с сорняками |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| WO2001085172A1 (en) * | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
| WO2009032123A2 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| KR20100065167A (ko) | 2007-08-29 | 2010-06-15 | 쉐링 코포레이션 | 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체 |
| RU2010111550A (ru) | 2007-08-29 | 2011-10-10 | Шеринг Корпорейшн (US) | 2,3-замещенные индольные производные для лечения вирусных инфекций |
| CN105294569A (zh) | 2007-09-17 | 2016-02-03 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| US8188104B2 (en) | 2007-09-17 | 2012-05-29 | Abbott Laboratories | Anti-infective agents and uses thereof |
| NZ584720A (en) | 2007-09-17 | 2012-07-27 | Abbott Lab | Uracil or thymine derivative for treating hepatitis c |
| EP2222672B1 (en) | 2007-11-16 | 2013-12-18 | Merck Sharp & Dohme Corp. | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| CA2705586A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| MX2011010047A (es) | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| SG174214A1 (en) | 2009-03-25 | 2011-10-28 | Abbott Lab | Antiviral compounds and uses thereof |
-
2010
- 2010-06-07 TW TW099118427A patent/TWI428332B/zh not_active IP Right Cessation
- 2010-06-07 AR ARP100101992A patent/AR077004A1/es unknown
- 2010-06-08 PE PE2011002042A patent/PE20120937A1/es active IP Right Grant
- 2010-06-08 MX MX2011013209A patent/MX2011013209A/es active IP Right Grant
- 2010-06-08 WO PCT/EP2010/057958 patent/WO2010142656A1/en active Application Filing
- 2010-06-08 KR KR1020127000604A patent/KR101431343B1/ko not_active IP Right Cessation
- 2010-06-08 PE PE2015001204A patent/PE20151092A1/es not_active Application Discontinuation
- 2010-06-08 MA MA34447A patent/MA33360B1/fr unknown
- 2010-06-08 MY MYPI2011005928A patent/MY157435A/en unknown
- 2010-06-08 JP JP2012514440A patent/JP5612678B2/ja active Active
- 2010-06-08 RU RU2011153788/04A patent/RU2540332C2/ru not_active IP Right Cessation
- 2010-06-08 ES ES10720797.9T patent/ES2525254T3/es active Active
- 2010-06-08 NZ NZ596646A patent/NZ596646A/en not_active IP Right Cessation
- 2010-06-08 CN CN201080025186.6A patent/CN102803216B/zh active Active
- 2010-06-08 EP EP10720797.9A patent/EP2440528B1/en active Active
- 2010-06-08 BR BRPI1010852A patent/BRPI1010852A2/pt not_active IP Right Cessation
- 2010-06-08 AU AU2010257592A patent/AU2010257592B2/en not_active Ceased
- 2010-06-08 SG SG2011091212A patent/SG176762A1/en unknown
- 2010-06-08 CA CA2764141A patent/CA2764141C/en not_active Expired - Fee Related
- 2010-06-09 US US12/797,308 patent/US8026253B2/en not_active Expired - Fee Related
-
2011
- 2011-08-18 US US13/212,742 patent/US8487103B2/en active Active
- 2011-11-16 CR CR20110605A patent/CR20110605A/es unknown
- 2011-11-17 IL IL216412A patent/IL216412A/en not_active IP Right Cessation
- 2011-11-24 CO CO11161639A patent/CO6400218A2/es active IP Right Grant
- 2011-12-05 ZA ZA2011/08921A patent/ZA201108921B/en unknown
- 2011-12-09 EC EC2011011513A patent/ECSP11011513A/es unknown
-
2013
- 2013-03-22 HK HK13103620.7A patent/HK1176070A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077004A1 (es) | Compuestos heterociclicos antivirales | |
| AR078397A1 (es) | Compuestos heterociclicos antivirales | |
| AR078732A1 (es) | Compuestos heterociclicos fusionados como moduladores del receptor de la orexina | |
| JP2012528166A5 (es) | ||
| ATE496043T1 (de) | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren | |
| PE20060620A1 (es) | Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1 | |
| AR045747A1 (es) | Derivados de 2,4 di (hetero)-arilamino-pirimidina como zap-70 inhibidores | |
| CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
| JP2012523457A5 (es) | ||
| AR057104A1 (es) | Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica | |
| PE20131086A1 (es) | Proceso para preparar compuestos antivirales | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| HRP20080227T3 (en) | Pyrrolidine derivatives as histamine receptors ligands | |
| AR070463A1 (es) | Compuestos de amina y eter que modulan el receptor cb2 | |
| BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
| AR067838A1 (es) | Compuestos pirrolicos, composiciones farmaceuticas que los contienen y usos | |
| ES2476592T3 (es) | Inhibidores del virus de la hepatitis C | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
| AR047533A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa | |
| ES2570784T3 (es) | Piridinas sustituidas como bloqueadores de los canales de sodio | |
| CO6251247A2 (es) | Imidazoquinolinas con propiedades inmuno-moduladoras | |
| AR064221A1 (es) | Inhibidores no nucleosidos de transcriptasa inversa | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |